Bionano Genomics (MEX:BNGO) Total Liabilities : MXN618.4 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Bionano Genomics Total Liabilities?

Bionano Genomics's Total Liabilities for the quarter that ended in Mar. 2025 was MXN618.4 Mil.

Bionano Genomics's quarterly Total Liabilities increased from Sep. 2024 (MXN757.96 Mil) to Dec. 2024 (MXN861.24 Mil) but then declined from Dec. 2024 (MXN861.24 Mil) to Mar. 2025 (MXN618.37 Mil).

Bionano Genomics's annual Total Liabilities increased from Dec. 2022 (MXN1,132.80 Mil) to Dec. 2023 (MXN2,007.15 Mil) but then declined from Dec. 2023 (MXN2,007.15 Mil) to Dec. 2024 (MXN861.24 Mil).

Bionano Genomics Total Liabilities Historical Data

The historical data trend for Bionano Genomics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionano Genomics Total Liabilities Chart

Bionano Genomics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

504.62

820.19

1,132.80

2,007.15

861.24

Bionano Genomics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															1,248.44	898.18	757.96	861.24	618.37

Bionano Genomics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bionano Genomics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	778.835	+	(76.832	+	0.00099999999996037
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	5.568	+	0	+	0)
	=	861.2

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	1599.007	-	737.77
	=	861.2

Bionano Genomics's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	540.26	+	(72.136	+	1.7763568394003E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	5.974	+	0	+	0)
	=	618.4

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	1604.209	-	985.84
	=	618.4

Bionano Genomics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bionano Genomics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bionano Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bionano Genomics Inc (MEX:BNGO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BNGO:USA

Address

9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.bionano.com

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.